Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Linerixibat: First Approval.

Drugs·2026

Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026

Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026

Same author

Taletrectinib: First Approval.

Drugs·2025

Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025

Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 3, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Tezepelumab: First Approval.

Sheridan M Hoy¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|February 20, 2022

Summary

This summary is machine-generated.

Tezepelumab is a novel biologic therapy targeting thymic stromal lymphopoietin (TSLP) for severe asthma. It offers a new treatment option for patients aged 12 and older, regardless of asthma phenotype or biomarkers.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

Related Experiment Videos

Last Updated: Oct 3, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

Area of Science:

Immunology
Respiratory Medicine
Pharmacology

Background:

Thymic stromal lymphopoietin (TSLP) is a key cytokine in asthma pathogenesis.
Severe asthma lacks targeted therapies for all patients.
Tezepelumab is a monoclonal antibody inhibiting TSLP.

Purpose of the Study:

To summarize the development of tezepelumab.
To highlight its first approval for severe asthma.
To review its potential in other respiratory and allergic conditions.

Main Methods:

Review of tezepelumab's development milestones.
Analysis of its regulatory approval process.
Summary of ongoing clinical development.

Main Results:

Tezepelumab received US FDA approval in December 2021 for severe asthma (add-on maintenance).
It is the first biologic approved for severe asthma without phenotype or biomarker restrictions.
Orphan drug designation received for eosinophilic esophagitis.

Conclusions:

Tezepelumab represents a significant advancement in severe asthma treatment.
Its broad applicability across asthma phenotypes marks a therapeutic shift.
Further development is ongoing for COPD, CRSwNP, and chronic spontaneous urticaria.